Merck Receives U.S. FDA Approval for Cholesterol Pill Lipfendra
Merck announced that the U.S. Food and Drug Administration (FDA) has approved its cholesterol-lowering pill, Lipfendra (enlicitide), marking a significant milestone as it is the first oral PCSK9 inhibitor to enter the market. This approval supports Merck's strategy to diversify beyond Keytruda, which faces patent expiration in 2028.
